Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 6/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858726 | 1.00 | ADRA1A (0.42) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| SCHEMBL5858106 | 1.00 | ADRA1A (0.42) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| SCHEMBL5858174 | 1.00 | ADRA1A (0.42) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| SCHEMBL5858315 | 1.00 | ADRA1A (0.42) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| SCHEMBL6246462 | 0.88 | ADRA1A (0.42) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| SCHEMBL5858732 | 0.87 | HTR1A (0.53) | ADRA1AHTR1AHTR1D | |
| SCHEMBL5858801 | 0.87 | HTR1A (0.53) | ADRA1AHTR1AHTR1D | |
| SCHEMBL5858707 | 0.87 | HTR1A (0.53) | ADRA1AHTR1AHTR1D | |
| SCHEMBL5858360 | 0.87 | HTR1A (0.53) | ADRA1AHTR1AHTR1D | |
| SCHEMBL5859373 | 0.87 | HTR1A (0.53) | ADRA1AHTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071197-B2 | N,N-disubstituted diazocycloalkanes | RECORDATI S.A. (CH) | 2006-07-04 | — | — | US | claimed |
| EP-1515961-A1 | N,N-DISUBSTITUTED DIAZOCYCLOALKANES USEFUL FOR THE TREATMENT OF CNS DISORDERS DUE TO SEROTONERGIC DYSFUNCTION | Recordati Ireland Limited (IE) | 2005-03-23 | — | — | EP | claimed |
| US-20040072822-A1 | N,N-disubstituted diazocycloalkanes | RECORDATI S.A. (CH) | 2004-04-15 | — | — | US | claimed |
| WO-2003106444-A1 | N,N-DISUBSTITUTED DIAZOCYCLOALKANES USEFUL FOR THE TREATMENT OF CNS DISORDERS DUE TO SEROTONERGIC DYSFUNCTION | RECORDATI S.A. (CH) | 2003-12-24 | — | — | WO | claimed |
| US-20060148821-A1 | N,N-disubstituted diazocycloalkanes | RECORDATI S.A. (CH) | 2006-07-06 | — | — | US | disclosed |
| US-7071197-B2 | N,N-disubstituted diazocycloalkanes | RECORDATI S.A. (CH) | 2006-07-04 | — | — | US | disclosed |
| EP-1515961-A1 | N,N-DISUBSTITUTED DIAZOCYCLOALKANES USEFUL FOR THE TREATMENT OF CNS DISORDERS DUE TO SEROTONERGIC DYSFUNCTION | Recordati Ireland Limited (IE) | 2005-03-23 | — | — | EP | disclosed |
| US-20040072822-A1 | N,N-disubstituted diazocycloalkanes | RECORDATI S.A. (CH) | 2004-04-15 | — | — | US | disclosed |
| WO-2003106444-A1 | N,N-DISUBSTITUTED DIAZOCYCLOALKANES USEFUL FOR THE TREATMENT OF CNS DISORDERS DUE TO SEROTONERGIC DYSFUNCTION | RECORDATI S.A. (CH) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072822-A1 | N,N-disubstituted diazocycloalkanes | HTR1D, HTR1A, HTR2C | ADRA1A 13/4885ADRA1B 18/4885ADRA1D 6/4885 |
| US-20060148821-A1 | N,N-disubstituted diazocycloalkanes | HTR1A, HTR1D, HTR2C | ADRA1A 20/4885ADRA1B 34/4885ADRA1D 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.